StartUPDATES: New developments for healthcare startups
Read about new developments from Stellar Health, Paige, venBio, and more.
venBio closes third fund for biopharma startup investment, valued at $394M
The San Francisco-based venture capital firm has recently led or participated in Series B and Series C funds of companies developing therapies in diseases like cancers and NASH.
presented by
Navina’s AI Copilot Eases the Value-Based Burden, Study Shows
A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.
ALX Oncology raises $105M in Series C round for checkpoint inhibitor development
The company is working to move its CD47-targeting drug, ALX148, into Phase II development. Another company, Forty Seven, is also developing a CD47-targeting therapy. CD47 is an immune checkpoint distinct from the ones targeted by currently marketed cancer immunotherapy drugs.
A $2B oncology deal goes bust at the hands of an activist investor
Activist investor venBio had a good Friday. Seattle Genetics and Immunomedics did not. The two latter companies agreed to fold on their $2 billion oncology deal, while Immunomedics' CEO and CSO also forfeited their jobs.